Venus Remedies Limited

NSEI:VENUSREM 株式レポート

時価総額:₹5.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Venus Remedies 配当金

配当金 基準チェック /06

Venus Remedies現在配当金を支払っていません。

主要情報

0%

配当利回り

0%

配当性向

業界平均利回り0.8%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
一株当たり利益₹21.31
3年後の配当利回り予想n/a

最近の配当金アップデート

更新なし

Recent updates

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13
Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14
Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Oct 31
Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Jun 03
Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Jul 15
Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

May 31
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30
I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24
Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16
Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11
Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14
We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23
Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22
Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

決済の安定と成長

配当データの取得

安定した配当: VENUSREMの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: VENUSREMの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Venus Remedies 配当利回り対市場
VENUSREM 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (VENUSREM)0%
市場下位25% (IN)0.3%
市場トップ25% (IN)1.1%
業界平均 (Pharmaceuticals)0.8%
3年後のアナリスト予想 (VENUSREM)n/a

注目すべき配当: VENUSREMは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: VENUSREMは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: VENUSREM Indian市場において目立った配当金を支払っていません。


株主配当金

キャッシュフローカバレッジ: VENUSREMが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘